Core Laboratories (CLB) Liabilities and Shareholders Equity (2022 - 2026)

Core Laboratories has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $587.7 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity changed 0.25% year-over-year to $587.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.4 billion (changed 0.19% YoY), and the FY2025 full-year result was $584.0 million, changed 0.19% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $587.7 million, up from $584.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $602.1 million in Q2 2025, with the low at $570.2 million in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $589.6 million across 5 years, with a median of $589.5 million in 2025.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity gained 4.21% — and 2025, when it declined 1.93%.
• Core Laboratories' Liabilities and Shareholders Equity stood at $578.4 million in 2022, then increased by 1.39% to $586.4 million in 2023, then slipped by 0.22% to $585.1 million in 2024, then slipped by 0.19% to $584.0 million in 2025, then increased by 0.64% to $587.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $587.7 million (Q1 2026), $584.0 million (Q4 2025), and $591.4 million (Q3 2025), per Business Quant data.